<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="138">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04324489</url>
  </required_header>
  <id_info>
    <org_study_id>DAS181-SARS-CoV-2</org_study_id>
    <nct_id>NCT04324489</nct_id>
  </id_info>
  <brief_title>DAS181 for Severe COVID-19: Compassionate Use</brief_title>
  <official_title>DAS181 for Severe COVID-19: Compassionate Use</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Renmin Hospital of Wuhan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ansun Biopharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Renmin Hospital of Wuhan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to investigate the safety and potential efficacy of DAS181 for
      the treatment of severe COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each eligible subject is treated with DAS181 for 10 days and observed for 28 days from the
      first day of administration.

      From day 1 to 10, once or twice a day, for 10 consecutive days, a total of 9 mg (7 ml)
      nebulized DAS181 is given. If DAS181 is given by twice a day, one vial containing 4.5 mg
      (3.5m1) DAS181 should be delivered with about 12-hour interval.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 6, 2020</start_date>
  <completion_date type="Actual">April 30, 2020</completion_date>
  <primary_completion_date type="Actual">April 16, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improved clinical status</measure>
    <time_frame>Day 14</time_frame>
    <description>Percent of subjects with improved clinical status</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Return to room air</measure>
    <time_frame>Day 14</time_frame>
    <description>Percent of subjects return to room air</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SARS-CoV-2 RNA</measure>
    <time_frame>28 days</time_frame>
    <description>time to SARS-CoV-2 RNA in the respiratory specimens being undetectable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discharge</measure>
    <time_frame>Days 14, 21, 28</time_frame>
    <description>Percent of patients discharge from hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>Day 14, 21, 28</time_frame>
    <description>All-cause mortality rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>DAS181 Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nebulized DAS181 9mg/day (4.5 mg bid/day) for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAS181</intervention_name>
    <description>Patient receives nebulized DAS181 (4.5 mg BID/day, a total 9 mg/day) for 10 days.</description>
    <arm_group_label>DAS181 Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Positive for RNA of SARS-CoV-2 from respiratory specimens or blood specimens

          2. Hypoxemic

          3. Severe COVID-19

          4. If female, subject must not be pregnant or nursing.

          5. Non-vasectomized males are required to practice effective birth control methods

          6. Capable of understanding and complying with procedures as outlined in the protocol as
             judged by the Investigator and able to sign informed consent form prior to the
             initiation of any screening or study-specific procedures.

        Exclusion Criteria:

          1. ALT or AST&gt; 8 x ULN

          2. (ALT or AST&gt; 3 x ULN) and (Total bilirubin&gt; 2.5 x ULN or INR&gt; 2.0 x ULN)

          3. Female subjects who have a positive pregnancy test and are breastfeeding

          4. Subjects using any other investigational antiviral drugs during the hospitalization
             before enrollment.

          5. Subjects participating in other clinical trials

          6. Subjects may be transferred to a non-participating hospital within 72 hours

          7. People who cannot cooperate well due to mental illness, have no self-control, and
             cannot express clearly

          8. Severe underlying diseases affecting survival

          9. Critical COVID-19 requiring mechanical ventilator at the time enrolled
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zuojiong Gong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Renmin Hospital of Wuhan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 25, 2020</study_first_submitted>
  <study_first_submitted_qc>March 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2020</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Renmin Hospital of Wuhan University</investigator_affiliation>
    <investigator_full_name>Gong Zuojiong</investigator_full_name>
    <investigator_title>Director, Department of Infectious Disease</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>DAS181</keyword>
  <keyword>Hypoxemia</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

